Gut Liver.
2014 Jan;8(1):64-69.
Efficacy and Safety of Tenofovir-Based Rescue Therapy for Chronic Hepatitis B Patients with Previous Nucleo(s/t)ide Treatment Failure
- Affiliations
-
- 1Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea. sykwonmd@hotmail.com
- 2Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
- 3Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University of Medicine and Science, Incheon, Korea.
Abstract
- BACKGROUND/AIMS
We investigated the efficacy and safety of tenofovir disoproxil fumarate (TDF)-based treatment in chronic hepatitis B (CHB) patients who failed previous antiviral therapies.
METHODS
Seventeen patients who failed to achieve virological responses during sequential antiviral treatments were included. The patients were treated with TDF monotherapy (four patients) or a combination of TDF and lamivudine (13 patients) for a median of 42 months. Hepatitis B virus (HBV) DNA and hepatitis B e antigen (HBeAg) were measured, and renal function was also monitored.
RESULTS
Prior to TDF therapy, 180 M, 204 I/V/S, 181 T/V, 236 T, and 184 L mutations were detected. After TDF therapy, the median HBV DNA level decreased from 4.6 log10 IU/mL to 2.0 log10 IU/mL and to 1.6 log10 IU/mL at 12 and 24 months, respectively. HBV DNA became undetectable (< or =20 IU/mL) in 14.3%, 41.7%, and 100% of patients after 12, 24, and 48 months of treatment, respectively. HBeAg loss was observed in two patients. Viral breakthrough occurred in five patients who had skipped their medication. No significant changes in renal function were observed.
CONCLUSIONS
TDF-based rescue treatment is effective in reducing HBV DNA levels and is safe for patients with CHB who failed prior antiviral treatments. Patients' adherence to medication is related to viral rebound.
Keyword
MeSH Terms
-
Adenine/*analogs & derivatives/therapeutic use
Adult
Biological Markers/metabolism
DNA, Viral/blood
Drug Resistance, Viral/drug effects
Drug Therapy, Combination
Female
Hepatitis B e Antigens/blood
Hepatitis B, Chronic/*drug therapy
Humans
Lamivudine/*therapeutic use
Male
Middle Aged
Organophosphonates/*therapeutic use
Reverse Transcriptase Inhibitors/*therapeutic use
Treatment Outcome
Adenine
Biological Markers
DNA, Viral
Hepatitis B e Antigens
Lamivudine
Organophosphonates
Reverse Transcriptase Inhibitors
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Is the tenofovir based therapy almighty for previous treatment failure in chronic hepatitis B?
- Entecavir Resistance at rtS202, rtM250 May Cause Poor Viral Response to Tenofovir-based Rescue Therapy in Chronic Hepatitis B
- Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus?
- Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients
- The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy
